The Drug Exists but Not Here

Cryptococcal meningitis causes approximately 194,000 cases and 147,000 deaths per year globally, representing 19% of all AIDS-related deaths. The WHO-recommended first-line treatment is a combination of flucytosine and amphotericin B, which substantially improves survival over alternatives. Flucytosine is registered in only a handful of African countries despite the continent bearing roughly 90% of global burden — meaning clinicians across most of sub-Saharan Africa are forced to use fluconazole monotherapy, which DNDi characterizes as "ineffective" as a first-line agent. The drug access gap is not a technical failure: flucytosine exists, works, and is off-patent. It is a regulatory and commercial failure.

With 147,000 deaths annually and fluconazole monotherapy producing markedly worse outcomes than guideline-recommended care, the treatment gap is directly and preventably lethal at scale. HIV funding reductions — including PEPFAR contractions — are compressing the health systems that manage most cryptococcal meningitis cases in the highest-burden countries. DNDi developed a sustained-release pellet formulation of flucytosine designed to replace the current every-six-hours dosing schedule with twice-daily administration, entered Phase II trials in Malawi and Tanzania in February 2025, and explicitly designed the formulation to be administrable to comatose patients via nasogastric tube. The underlying problem — unregistered essential medicine, no commercial sponsor, collapsing donor funding — will persist regardless of whether the new formulation succeeds unless access and registration structures change.

Flucytosine has been on WHO's Essential Medicines List, and international advocacy has called for expanded registration for years, but the absence of a commercial sponsor with market interest in low-income country registration has meant that national regulatory submissions have not occurred at scale. The current formulation (six-hourly tablets) is problematic for the typical patient presentation: severely ill, often comatose, requiring intensive nursing support for medication administration. Generic manufacturers have not entered the market at prices or volumes that would trigger national registration efforts. Amphotericin B, the companion drug, requires IV administration and renal monitoring that is already at the edge of feasibility in many district hospitals. Efforts to expand access have relied on donated or donor-purchased supply pipelines that are structurally fragile, as PEPFAR-era funding contractions are demonstrating in real time.

A twice-daily sustained-release formulation appropriate for nasogastric administration (DNDi's current Phase II candidate) would reduce the clinical burden of administering flucytosine to severely ill patients, potentially expanding the settings where guideline-recommended treatment is feasible. But formulation alone does not solve registration: coordinated regulatory submissions across high-burden African countries, ideally through the African Medicines Agency or national regulatory authority coalitions, would need to accompany any new product launch. A viable non-donor supply mechanism — whether through government procurement pools, tiered pricing agreements with generic manufacturers, or access-conditioned licensing — is necessary for durability.

A policy or health systems team could map the exact regulatory status of flucytosine across the 30 highest-burden countries, identify where the submission gap is a resource problem versus a political economy problem, and model what a coordinated regional registration campaign would cost and require. A drug delivery or formulation team could engage with the Phase II trial design to understand what physical and stability specifications a sustained-release pellet formulation must meet for tropical primary care settings. A global health financing team could analyze what access-conditioned licensing structures have succeeded for other off-patent essential medicines and assess whether any are applicable here.